166 related articles for article (PubMed ID: 27749622)
21. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors.
Porfyriou E; Letsa S; Kosmas C
World J Clin Oncol; 2021 Sep; 12(9):746-766. PubMed ID: 34631440
[TBL] [Abstract][Full Text] [Related]
23. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
24. Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Necchi A; Miceli R; Pedrazzoli P; Giannatempo P; Secondino S; Di Nicola M; Farè E; Raggi D; Magni M; Matteucci P; Longoni P; Milanesi M; Paternò E; Ravagnani F; Arienti F; Nicolai N; Salvioni R; Carlo-Stella C; Gianni AM
Clin Genitourin Cancer; 2014 Jun; 12(3):196-202.e1. PubMed ID: 24361054
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
26. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
Chaudhary UB; Damon LE; Rugo HS; Linker CA; Navarro W; Small EJ
Am J Clin Oncol; 2005 Apr; 28(2):130-7. PubMed ID: 15803005
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
28. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
Haverkos BM; Huang Y; Elder P; O'Donnell L; Scholl D; Whittaker B; Vasu S; Penza S; Andritsos LA; Devine SM; Jaglowski SM
Bone Marrow Transplant; 2017 Apr; 52(4):561-566. PubMed ID: 28067870
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience.
Agarwal R; Dvorak CC; Stockerl-Goldstein KE; Johnston L; Srinivas S
Bone Marrow Transplant; 2009 Apr; 43(7):547-52. PubMed ID: 18997833
[TBL] [Abstract][Full Text] [Related]
30. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Topczewska M; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Grygoruk-Wiśniowska I; Krawczyk-Kuliś M; Romejko-Jarosińska J; Frączak E; Wróbel T; Piątkowska-Jakubas B; Mądry K; Boguradzki P; Król M; Kozioł M; Hus M; Kopińska A; Dmoszyńska A; Basak GW; Dwilewicz-Trojaczek J
J Clin Apher; 2021 Jun; 36(3):443-453. PubMed ID: 33592119
[TBL] [Abstract][Full Text] [Related]
31. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
32. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
33. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
[TBL] [Abstract][Full Text] [Related]
34. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.
Perkins JB; Shapiro JF; Bookout RN; Yee GC; Anasetti C; Janssen WE; Fernandez HF
Am J Hematol; 2012 Jul; 87(7):673-7. PubMed ID: 22674468
[TBL] [Abstract][Full Text] [Related]
35. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT).
De Giorgi U; Richard S; Badoglio M; Kanfer E; Bourrhis JH; Nicolas-Virelizier E; Vettenranta K; Lioure B; Martin S; Dreger P; Schuler MK; Thomson K; Scarpi E; Rosti G; Selle F; Mangili G; Lanza F; Bregni M;
Ann Oncol; 2017 Aug; 28(8):1910-1916. PubMed ID: 28510616
[TBL] [Abstract][Full Text] [Related]
36. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
[TBL] [Abstract][Full Text] [Related]
37. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
38. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
39. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
Saure C; Weigelt C; Schroeder T; Klärner V; Galonska L; Haas R; Kobbe G
Acta Haematol; 2010; 124(4):235-8. PubMed ID: 21099212
[TBL] [Abstract][Full Text] [Related]
40. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
